Fig. 4

CF microbiome in the Post-azithromycin sputum samples. a Alpha diversity (within patients) of samples from patients who experienced one or more than 1 PEx event after azithromycin initiation based on Shannon diversity index (SDI) metrics for the entire cohort (n = 38 patients) and those completely naïve (n = 29). b ASVs that were identified to be significantly different (p adjusted < 0.05) in relative abundance between patients with non or more than 1 PEx event during the post period, as detected by DESeq2. c Alpha diversity of samples from patients who were naïve to azithromycin or who had not been exposed to azithromycin within at least 3 years. d ASV that was identified to be significantly different (p adjusted < 0.05) in relative abundance between naive and Non-naïve patients, as detected by DESeq2. For a and c, Wilcoxon rank sum test was performed, and boxplots show the median with IQR and the ends of the whiskers mark the 10th and the 90th percentiles. ASV: amplicon sequence variants